Pfizer Reports Strong Q1 Growth Driven by New Products
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 42 minutes ago
0mins
Should l Buy PFE?
Source: Yahoo Finance
- Significant Revenue Growth: Pfizer's Q1 revenue reached $14.45 billion, exceeding analyst expectations of $13.77 billion with a year-on-year growth of 5.4%, reflecting strong performance in new products and acquisitions, particularly in oncology and migraine therapies.
- Strong New Product Performance: CEO Albert Bourla highlighted a 22% revenue increase from new products and acquisitions, particularly noting the successful integration of Seagen and robust demand for Nurtec, which further solidifies Pfizer's competitive position in the market.
- Improved Legal and Financial Clarity: Management pointed to positive developments in legal settlements that have enhanced clarity on post-2028 growth and cash flow, providing support for the company's long-term strategic planning.
- Cost Management and R&D Investments: CFO David Denton emphasized that ongoing cost management and targeted R&D investments were key contributors to the quarter's outperformance, demonstrating Pfizer's efficiency in resource allocation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.960
Low
24.00
Averages
28.56
High
35.00
Current: 25.960
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Reports Strong Q1 Growth Driven by New Products
- Significant Revenue Growth: Pfizer's Q1 revenue reached $14.45 billion, exceeding analyst expectations of $13.77 billion with a year-on-year growth of 5.4%, reflecting strong performance in new products and acquisitions, particularly in oncology and migraine therapies.
- Strong New Product Performance: CEO Albert Bourla highlighted a 22% revenue increase from new products and acquisitions, particularly noting the successful integration of Seagen and robust demand for Nurtec, which further solidifies Pfizer's competitive position in the market.
- Improved Legal and Financial Clarity: Management pointed to positive developments in legal settlements that have enhanced clarity on post-2028 growth and cash flow, providing support for the company's long-term strategic planning.
- Cost Management and R&D Investments: CFO David Denton emphasized that ongoing cost management and targeted R&D investments were key contributors to the quarter's outperformance, demonstrating Pfizer's efficiency in resource allocation.
See More
Pfizer's Patent Extension Boosts Future Growth Prospects
- Revenue Overview: Pfizer reported over $100 billion in revenue in 2022, primarily driven by COVID vaccines and treatments, but saw stagnation at $63 billion in 2023, highlighting post-pandemic growth challenges.
- Acquisition and Pipeline Rebuilding: The $43 billion acquisition of Seagen is part of Pfizer's strategy to rebuild its pipeline, although significant revenue from new drugs is not expected until 2028, enhancing its oncology portfolio's competitiveness.
- Patent Protection Extension: Pfizer secured agreements with three competitors to extend Vyndamax's patent protection until 2031, providing additional cash flow to support the completion of its 32 ongoing phase 3 trials.
- Future Growth Potential: Pfizer's CEO indicated that the patent resolution for Vyndamax could significantly alter the company's growth trajectory post-2028, with expectations of entering a high-single-digit revenue CAGR phase starting in 2029, boosting investor confidence.
See More
Pharma and Biotech Deal-Making Trends Remain Strong
- Surge in Transactions: Eric Tokat from Centerview Partners noted that 34 significant transactions are expected in Q4 2025 and Q1 2026, indicating a robust trend in pharma and biotech deal-making, particularly with an increase in early-stage candidate deals compared to previous years.
- Expansion into New Areas: Clive Meanwell from Population Health Partners highlighted that while recent deals have focused on oncology and obesity, there is an expectation for expansion into other areas, especially central nervous system assets, showcasing the market's potential for diversification over the next few years.
- Merck's Acquisition Frenzy: Merck has spent nearly $26 billion on M&A from April 2025 to April 2026, driven by the impending patent expiration of its blockbuster oncology therapy Keytruda in 2028, prompting the company to accelerate transactions to maintain its competitive edge in the market.
- Limited Macro Impact: Despite challenges such as inflation, oil prices, and the ongoing Iran war, Tokat believes that pharma and biotech deal-making will remain active, indicating strong industry resilience capable of withstanding external shocks.
See More
Trump's Drug Policy May Harm US Biopharma Innovation
- Drug Prices vs. Innovation: PhRMA COO Lori Reilly indicated that Trump's 'Most Favored Nation' drug policy could depress funding for US drug R&D, thereby weakening the country's biopharma innovation capabilities, particularly in competition with China.
- Policy Impact Analysis: Reilly emphasized that adopting international drug policies that undervalue innovation could invite China to surpass the US in biopharma innovation, affecting future market leadership.
- Trade Tool Recommendations: She suggested that the Trump administration should leverage Section 301 of the Trade Act more to impose tariffs and import restrictions on unjustifiable trade practices, thereby protecting US intellectual property and market policies.
- Market Strategy Adjustments: Experts at the conference noted that companies might opt not to sell drugs in Europe due to profit-maximizing strategies, potentially leading to increased drug purchases from Chinese biopharma firms, further impacting US market share.
See More
Eli Lilly Leads the Weight Loss Drug Market
- Market Leadership: Eli Lilly is positioned to lead the weight loss drug market, projected to reach $100 billion in the next decade from a current value of $40 billion, indicating strong performance in a rapidly growing sector.
- Significant Sales Growth: In the recent quarter, Mounjaro and Zepbound generated over $12 billion in total sales, reflecting robust consumer demand for GLP-1 drugs and the company's competitive edge in this field.
- New Product Launch: Lilly received FDA approval for its oral weight loss drug Foundayo, treating 20,000 patients in its first month, showcasing strong appeal among new users and potentially providing new growth avenues for the company.
- Managing Competitive Risks: While new products from Novo Nordisk and other competitors pose risks to Zepbound sales, the introduction of Foundayo may broaden the potential audience for GLP-1 drugs, creating new market opportunities for Eli Lilly.
See More
Hantavirus Outbreak Sparks Rally in Biotech Stocks
- Impact Assessment: The recent hantavirus outbreak on a cruise ship has sparked a rally in the biotech sector; however, due to its transmission primarily through contact and a much lower contagion rate compared to COVID-19, the market for hantavirus vaccines may be limited, affecting the long-term profitability of related companies.
- Predicting Winners: Even if the situation worsens, it remains challenging for investors to identify which companies will successfully develop hantavirus vaccines, as historical data shows that even major pharmaceutical firms like Sanofi and Merck failed to dominate the COVID-19 vaccine market, highlighting the complexities of investment risks.
- Return on Investment Risks: Even if investors choose companies that successfully develop vaccines, market-beating returns are not guaranteed; data indicates that companies like Pfizer and Moderna, which excelled during the COVID-19 peak, have underperformed the S&P 500 since then, reflecting market uncertainties.
- Potential Investment Opportunities: Despite challenges, Moderna and Pfizer are still considered attractive vaccine manufacturers; Moderna has been working on a hantavirus vaccine and has a promising pipeline, while Pfizer's replenished pipeline and upcoming pivotal trials make it a stock worth serious consideration for long-term returns.
See More
Pfizer Reports Strong Q1 Growth Driven by New Products
- Significant Revenue Growth: Pfizer's Q1 revenue reached $14.45 billion, exceeding analyst expectations of $13.77 billion with a year-on-year growth of 5.4%, reflecting strong performance in new products and acquisitions, particularly in oncology and migraine therapies.
- Strong New Product Performance: CEO Albert Bourla highlighted a 22% revenue increase from new products and acquisitions, particularly noting the successful integration of Seagen and robust demand for Nurtec, which further solidifies Pfizer's competitive position in the market.
- Improved Legal and Financial Clarity: Management pointed to positive developments in legal settlements that have enhanced clarity on post-2028 growth and cash flow, providing support for the company's long-term strategic planning.
- Cost Management and R&D Investments: CFO David Denton emphasized that ongoing cost management and targeted R&D investments were key contributors to the quarter's outperformance, demonstrating Pfizer's efficiency in resource allocation.
See More
Pfizer's Patent Extension Boosts Future Growth Prospects
- Revenue Overview: Pfizer reported over $100 billion in revenue in 2022, primarily driven by COVID vaccines and treatments, but saw stagnation at $63 billion in 2023, highlighting post-pandemic growth challenges.
- Acquisition and Pipeline Rebuilding: The $43 billion acquisition of Seagen is part of Pfizer's strategy to rebuild its pipeline, although significant revenue from new drugs is not expected until 2028, enhancing its oncology portfolio's competitiveness.
- Patent Protection Extension: Pfizer secured agreements with three competitors to extend Vyndamax's patent protection until 2031, providing additional cash flow to support the completion of its 32 ongoing phase 3 trials.
- Future Growth Potential: Pfizer's CEO indicated that the patent resolution for Vyndamax could significantly alter the company's growth trajectory post-2028, with expectations of entering a high-single-digit revenue CAGR phase starting in 2029, boosting investor confidence.
See More
Pharma and Biotech Deal-Making Trends Remain Strong
- Surge in Transactions: Eric Tokat from Centerview Partners noted that 34 significant transactions are expected in Q4 2025 and Q1 2026, indicating a robust trend in pharma and biotech deal-making, particularly with an increase in early-stage candidate deals compared to previous years.
- Expansion into New Areas: Clive Meanwell from Population Health Partners highlighted that while recent deals have focused on oncology and obesity, there is an expectation for expansion into other areas, especially central nervous system assets, showcasing the market's potential for diversification over the next few years.
- Merck's Acquisition Frenzy: Merck has spent nearly $26 billion on M&A from April 2025 to April 2026, driven by the impending patent expiration of its blockbuster oncology therapy Keytruda in 2028, prompting the company to accelerate transactions to maintain its competitive edge in the market.
- Limited Macro Impact: Despite challenges such as inflation, oil prices, and the ongoing Iran war, Tokat believes that pharma and biotech deal-making will remain active, indicating strong industry resilience capable of withstanding external shocks.
See More
Trump's Drug Policy May Harm US Biopharma Innovation
- Drug Prices vs. Innovation: PhRMA COO Lori Reilly indicated that Trump's 'Most Favored Nation' drug policy could depress funding for US drug R&D, thereby weakening the country's biopharma innovation capabilities, particularly in competition with China.
- Policy Impact Analysis: Reilly emphasized that adopting international drug policies that undervalue innovation could invite China to surpass the US in biopharma innovation, affecting future market leadership.
- Trade Tool Recommendations: She suggested that the Trump administration should leverage Section 301 of the Trade Act more to impose tariffs and import restrictions on unjustifiable trade practices, thereby protecting US intellectual property and market policies.
- Market Strategy Adjustments: Experts at the conference noted that companies might opt not to sell drugs in Europe due to profit-maximizing strategies, potentially leading to increased drug purchases from Chinese biopharma firms, further impacting US market share.
See More
Eli Lilly Leads the Weight Loss Drug Market
- Market Leadership: Eli Lilly is positioned to lead the weight loss drug market, projected to reach $100 billion in the next decade from a current value of $40 billion, indicating strong performance in a rapidly growing sector.
- Significant Sales Growth: In the recent quarter, Mounjaro and Zepbound generated over $12 billion in total sales, reflecting robust consumer demand for GLP-1 drugs and the company's competitive edge in this field.
- New Product Launch: Lilly received FDA approval for its oral weight loss drug Foundayo, treating 20,000 patients in its first month, showcasing strong appeal among new users and potentially providing new growth avenues for the company.
- Managing Competitive Risks: While new products from Novo Nordisk and other competitors pose risks to Zepbound sales, the introduction of Foundayo may broaden the potential audience for GLP-1 drugs, creating new market opportunities for Eli Lilly.
See More
Hantavirus Outbreak Sparks Rally in Biotech Stocks
- Impact Assessment: The recent hantavirus outbreak on a cruise ship has sparked a rally in the biotech sector; however, due to its transmission primarily through contact and a much lower contagion rate compared to COVID-19, the market for hantavirus vaccines may be limited, affecting the long-term profitability of related companies.
- Predicting Winners: Even if the situation worsens, it remains challenging for investors to identify which companies will successfully develop hantavirus vaccines, as historical data shows that even major pharmaceutical firms like Sanofi and Merck failed to dominate the COVID-19 vaccine market, highlighting the complexities of investment risks.
- Return on Investment Risks: Even if investors choose companies that successfully develop vaccines, market-beating returns are not guaranteed; data indicates that companies like Pfizer and Moderna, which excelled during the COVID-19 peak, have underperformed the S&P 500 since then, reflecting market uncertainties.
- Potential Investment Opportunities: Despite challenges, Moderna and Pfizer are still considered attractive vaccine manufacturers; Moderna has been working on a hantavirus vaccine and has a promising pipeline, while Pfizer's replenished pipeline and upcoming pivotal trials make it a stock worth serious consideration for long-term returns.
See More
